Appropriateness to set a group health-based guidance value for zearalenone and its modified forms

Wallace, HeatherJan, AlexanderBarregård, LarsBignami, MargheritaCeccatelli, SandraCottrill, BruceDinovi, MichaelEdler, LutzGrasl-Kraupp, BettinaHogstrand, ChristerHoogenboom, Laurentius (Ron)Knutsen, Helle KatrineNebbia, Carlo StefanoOswald, IsabellePetersen, AnnetteRogiers, Vera MariaRose, MartinRoudot, Alain-ClaudeSchwerdtle, TanjaVleminckx, ChristianeVollmer, GünterEFSA Panel on Contaminants in the Food Chain (CONTAM)2016-12-012016-12-012016-04Wallace, H, Jan, A, Barregård, L, Bignami, M, Ceccatelli, S, Cottrill, B, Dinovi, M, Edler, L, Grasl-Kraupp, B, Hogstrand, C, Hoogenboom, L, Knutsen, H K, Nebbia, C S, Oswald, I, Petersen, A, Rogiers, V M, Rose, M, Roudot, A-C, Schwerdtle, T, Vleminckx, C, Vollmer, G & EFSA Panel on Contaminants in the Food Chain (CONTAM) 2016, 'Appropriateness to set a group health-based guidance value for zearalenone and its modified forms', EFSA Journal, vol. 14, no. 4, 4425, pp. 1-46. https://doi.org/10.2903/j.efsa.2016.44251831-4732http://hdl.handle.net/2164/7792The Panel wishes to thank the members of the Working Group on group HBGVs for mycotoxins and their modiﬁed forms: Jan Alexander, Chiara Dall’Asta, Arno Gutleb, Manfred Metzler, Isabelle Oswald and Dominique Parent-Massin for the preparatory work on this scientiﬁc opinion, and the EFSA staff member Hans Steinkellner for the support provided to this scientiﬁc opinion.4621578engzearalenonemodified formsmetabolitesgroup tolerable daily intakeoestrogenicityrelative potency factorsR MedicineRAppropriateness to set a group health-based guidance value for zearalenone and its modified formsJournal article10.2903/j.efsa.2016.4425144